spacer
home > ebr > summer 2002 > finding the meaning of the gene
PUBLICATIONS
European Biopharmaceutical Review

Finding the Meaning of the Gene

The last decade has seen genomics come into its own, with the sequencing of the complete human genome, and the encoding of approximately 100,000 proteins, of which several thousand are of potential pharmaceutical use. This has prompted many institutes in academia, as well as Big Pharma and numerous new companies, to participate in this revolutionary work. A broad range of techniques have now been developed to compare healthy and malignant cells or tissues to find 'the needle in the haystack', that is the genes that are responsible for diseases. Stock markets worldwide have recognised these billion dollar opportunities and funded the search for this encoding which could potentially discover valuable new drugs.All these efforts have led to an enormous number of nucleotide sequences that need to undergo 'proof of principle' by translating them into a functional protein and in vivo testing. Screening, production and test systems are extremely time sensitive and often crucial for the survival of a drug through the development cycle, not to mention crucial for the survival of companies active in the field of genomics. Therefore protein production and assay systems need to be chosen carefully with respect to speed, performance and the possibility of eventual mass production, without changing the system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michael Zang-Gandor, CEO of EugeneX Biotechnologies GmbH

Michael Zang-Gandor is President and CEO of EugeneX Biotechnologies GmbH, a Swiss-based research, development and service company engaged in protein production, strain, cell line and process development.
As the co-founder he specialised in the expression of recombinant proteins in serum-free mammalian cells at ETH-Zurich and Novartis AG.

spacer
Michael Zang-Gandor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement